# | Date | Analyst Firm | Upside/Downside | Price Target Change | Rating Change | Current Rating |
---|
Needham analyst Serge Belanger reiterates Trevi Therapeutics (NASDAQ:TRVI) with a Buy and maintains $8 price target.
Trevi Therapeutics (NASDAQ:TRVI) reported quarterly losses of $(0.11) per share which missed the analyst consensus estimate of ...
Trevi Therapeutics, Inc. (NASDAQ:TRVI), a clinical-stage biopharmaceutical company developing the investigational therapy Hadu...
Needham analyst Serge Belanger reiterates Trevi Therapeutics (NASDAQ:TRVI) with a Buy and maintains $8 price target.
Oppenheimer analyst Leland Gershell maintains Trevi Therapeutics (NASDAQ:TRVI) with a Outperform and maintains $9 price target.
Needham analyst Serge Belanger reiterates Trevi Therapeutics (NASDAQ:TRVI) with a Buy and maintains $8 price target.
Trevi Therapeutics (NASDAQ:TRVI) reported quarterly losses of $(0.08) per share which beat the analyst consensus estimate of $(...
Companies Reporting Before The Bell • UP Fintech Holding (NASDAQ:TIGR) is expected to report quarterly earnings at $0.07 per s...